SB623's use of Japan's early approval system and launch in Japan
A product-specific regulatory and commercialisation theme concerning the aim of bringing SB623 to market early in Japan, including NHI price listing and the start of sales, by using Japan's early approval system for regenerative medical products.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.